Physician profile
Michael Higgins
NPI 1730251661
$2,604.00
in general payments reported to CMS, 2019-2025
26 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $451 · 2021: $68.87 · 2022: $182 · 2024: $120 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $405.96 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $196.53 | 2019-2022 | |
| Pfizer INC. | $183.85 | 2019-2025 | |
| Stryker Corporation | $173.22 | 2025 | Mako |
| Amgen INC. | $170.03 | 2019-2020 | |
| Novo Nordisk INC | $168.96 | 2019-2024 | Wegovy |
| Lilly USA, LLC | $166.39 | 2019-2020 | |
| Esperion Therapeutics, INC. | $157.72 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $133.29 | 2019-2020 | |
| Boston Scientific Corporation | $126.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.58 | 2019-2020 | |
| Eisai INC. | $104.29 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $64.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.43 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $63.28 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $59.94 | 2019-2020 | |
| Abbvie INC. | $47.85 | 2019 | |
| Sanofi Pasteur INC. | $38.31 | 2019-2020 | |
| Glaxosmithkline, LLC. | $37.59 | 2019 | |
| Merz North America, INC. | $34.84 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.08 | 2019 | |
| Antares Pharma, INC. | $19.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.73 | 2019 | |
| Ge Healthcare | $15.37 | 2019 | |
| Allergan, INC. | $12.89 | 2020 | |
| Orexo US, INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.